en POLSKI
eISSN: 2300-8660
ISSN: 0031-3939
Pediatria Polska - Polish Journal of Paediatrics
Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Contact Instructions for authors Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
1/2021
vol. 96
 
Share:
Share:
abstract:
Review paper

Primary immune thrombocytopenia in children

Agnieszka Książek
1
,
Tomasz Szczepański
1

  1. Department od Pediatric Hematology and Oncology, Zabrze, Medical University of Silesia, Katowice, Poland
Pediatr Pol 2021; 96 (1): 53–59
Online publish date: 2021/03/28
View full text Get citation
 
PlumX metrics:
Primary immune thrombocytopenia (ITP) is usually a benign and self-limiting disease in children. Due to the complex pathogenesis involving different immunological processes, its course may be unpredictable. The goal of therapy is to prevent severe, dangerous bleeding, especially intracranial bleeding. In addition to purpura, i.e. ecchymoses and bruises on the skin, mucosal bleeding may occur, e.g. from nose, gums, excessive menstrual bleeding, as well as severe bleeding from the gastrointestinal or urinary tract. First-line therapy relies on glucocorticoids (GKS) or intravenous immunoglobulins (IVIgG). The next stage of treatment is the inclusion of other immunosuppressive drugs or cytotoxic drugs. The introduction of thrombopoietin receptor agonists (TPO-RAs) for the treatment of this disease has been the biggest progress over the past 20 years. TPO-RAs are treatment of choice for chronic ITP. Splenectomy is now reserved only for children with chronic ITP resistant to thrombopoietin receptor agonists..
keywords:

primary immune thrombocytopenia, children, treatment